Stroke Device specialist Silk Road Medical, Inc. tells us that more than 100,000 TCAR procedures have been performed to date.
Background
Globally 15 million people suffer a stroke each year. Of these, more than 800,000 are attributed to carotid artery disease in the US alone. The growing prevalence of carotid artery disease has driven the quest for an improved approaches to stroke prevention.
It’s almost a decade since Silk Road first appeared on our pages. The company’s technologists are on a mission to reduce the risk of stroke during treatment of carotid artery disease. Indeed the company pioneered the Transcarotid Artery Revascularization (TCAR) procedure. Furthermore it developed the ENROUTE® Transcarotid Neuroprotection System (ENROUTE NPS). This system supports the procedure with its patented flow reversal technology. Clinically, TCAR compares well with traditional open surgery (carotid endarterectomy or “CEA”). In fact it has demonstrated a lower risk of acute heart attack, less occurrences of nerve injury, shorter time required to perform the procedure, and a reduced length of stay at the hospital for patients.
TCAR with the ENROUTE Transcarotid Neuroprotection and Stent System
TCAR is a clinically proven procedure used by vascular specialist to treat blockages in the carotid artery. It combines surgical principles of neuroprotection with minimally invasive endovascular techniques. The ENROUTE Transcarotid Stent is intended for patients at high risk and standard risk for complications from CEA. It works in conjunction with the ENROUTE NPS during the TCAR procedure. The ENROUTE NPS is a first-in-class device that clinicians use to directly access the common carotid artery. Uniquely it employs high-rate temporary blood flow reversal to protect the brain from stroke while delivering and implanting the ENROUTE Transcarotid Stent.
Clinician comments
“A growing number of patients come to us looking for a solution that is minimally invasive and requires less downtime so they can get back to their daily lives,” said Dr. Gregg Landis, System Chief of Vascular Surgery at Northwell Health. “It’s incredible that Silk Road was able to not only address that need by creating the TCAR procedure, but also achieve such widespread adoption in a short period of time. TCAR has transformed the way we approach treating carotid artery disease while consistently delivering positive patient outcomes.”
Chas McKhann, CEO of Silk Road comments
“Completing the 100,000th TCAR procedure is the culmination of more than 15 years’ worth of work by members of the Silk Road Medical team and the healthcare providers we work with.”
“As we celebrate this important milestone, we remain excited and motivated to establish TCAR as the standard of care for addressing carotid artery disease.”
Source: Globe Newswire
